SPX4,026.12-1.14 -0.03%
DIA343.52+1.57 0.46%
IXIC11,226.36-58.96 -0.52%

Citigroup Maintains Buy on Cano Health, Lowers Price Target to $5

Benzinga · 11/16/2022 07:46
Citigroup analyst Jason Cassorla maintains Cano Health (NYSE:CANO) with a Buy and lowers the price target from $7 to $5.